Insight

Aug 29, 2025, 16:35

Florida Invests 3.3 Million Dollars in TempShield to Cut Infection Deaths in Chemo Patients

Florida Cancer Specialists and Research Institute has been awarded $3.3M from the Florida Cancer Innovation Fund to expand TempShield – an FDA-cleared wearable that continuously monitors body temperature in chemotherapy patients.

Why it matters:

New ASCO data from Ellis Medicine (Roswell Park Cancer Care Network) showed TempShield use was linked to a 90% reduction in infection-related mortality and 79% fewer hospital days.
Fevers were detected up to 72 hours before symptoms, enabling earlier intervention.
Florida’s adoption positions the state as a potential national model for integrating proactive infection monitoring into oncology care.

Title: Long-term continuous temperature monitoring at a community cancer center: Towards a new standard of care in oncology

Authors: Tallat Mahmood, Elise Currier, Alyssa Arogosa, Mayur Pabba, Zetta Georgia Keleki, Grace Li, and Nicholas Montalto

You can read the Full Article on the Journal of Clinical Oncology.

Florida Invests 3.3 Million Dollars in TempShield to Cut Infection Deaths in Chemo Patients

You can find more posts about Florida Cancer Specialists and Research Institute on OncoDaily.

Alyssa Arogosa cancer Elise Currier Florida Cancer Innovation Fund Florida Cancer Specialists and Research Institute Grace Li Journal of Clinical Oncology Mayur Pabba Nicholas Montalto OncoDaily Oncology Tallat Mahmood temperature monitoring TempShield Zetta Georgia Keleki

Why Is Financial Wellness Crucial for Physicians and Health Care Professionals?

BOT/BAL Advancements, BATTMAN Trial, FDA Approval Challenges and Key Highlights from Agenus Stakeholder Briefing

10 Leading Experts Join OncoDaily Journal Editorial Team

Top 10 Oncogrants of the Week: Fueling Cancer Research and Innovation

Soon-Shiong’s “Bioshield” Sparks Early Promise in Recurrent GBM, With 2 Near-CRs and 100% Disease Control